Towards Simulating the Human Brain

The human brain has been described as “the most complex object in the universe.” Its meshwork of 86 billion neurons,84 billion glial cells, and over 150 trillion synapses may seem intractable. Nonetheless, efforts to comprehensively map, understand, and even computationally reproduce this structure are underway. Large collectives of researchers have come together, working in concert towards these goals. The Human Brain Project (HBP) and its precursor, the Blue Brain Project, have spearheaded the brain simulation goal.Some other notable organizations include the China Brain Project, the BRAIN Initiative. On a scale which parallels the space program and the Human Genome Project, neuroscience may be approaching a revolution

Synthetic biology design as a paradigm shift toward manufacturing affordable adeno-associated virus gene therapies

Gene therapy has demonstrated enormous potential for changing how we combat disease. By directly engineering the genetic composition of cells, it provides a broad range of options for improving human health. Adeno-associated viruses (AAVs) represent a leading gene therapy vector and are expected to address a wide range of conditions in the coming decade. Three AAV therapies have already been approved by the FDA to treat Leber\u27s congenital amaurosis, spinal muscular atrophy, and hemophilia B. Yet these therapies cost around $850,000,$2,100,000, and $3,500,000, respectively. Such prices limit the broad applicability of AAV gene therapy and make it inaccessible to most patients. Much of this problem arises from the high manufacturing costs of AAVs. At the same time, the field of synthetic biology has grown rapidly and has displayed a special aptitude for addressing biomanufacturing problems. Here, we discuss emerging efforts to apply synthetic biology design to decrease the price of AAV production, and we propose that such efforts could play a major role in making gene therapy much more widely accessible